➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Dow
Medtronic
Merck
Boehringer Ingelheim

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Patent: 9,492,449

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,492,449
Title:Therapies for hematologic malignancies
Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administering a compound of formula A, ##STR00001## wherein R is H, halo, or C1-C6 alkyl; R\' is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient; and administering at least one additional therapeutic agent.
Inventor(s): Gallatin; W. Michael (Mercer Island, WA), Ulrich; Roger G. (Foster City, CA), Giese; Neill A. (San Francisco, CA), Lannutti; Brian (Seattle, WA), Miller; Langdon (Lebanon, NJ), Jahn; Thomas M. (Seattle, WA)
Assignee: Gilead Calistoga LLC (Foster City, CA)
Application Number:13/417,185
Patent Claims:see list of patent claims

Details for Patent 9,492,449

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Gilead Calistoga LLC (Foster City, CA) 2028-11-13 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Gilead Calistoga LLC (Foster City, CA) 2028-11-13 RX search
Novartis ARZERRA ofatumumab INJECTABLE; INJECTION 125326 001 2009-10-26   Start Trial Gilead Calistoga LLC (Foster City, CA) 2028-11-13 RX search
Novartis KESIMPTA ofatumumab SOLUTION;SUBCUTANEOUS 125326 002 2009-10-26   Start Trial Gilead Calistoga LLC (Foster City, CA) 2028-11-13 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Gilead Calistoga LLC (Foster City, CA) 2028-11-13 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Gilead Calistoga LLC (Foster City, CA) 2028-11-13 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Moodys
Medtronic
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.